Compositions and methods are provided for production of cells useful in regenerative therapies.

The present invention relates to a method of cultivating an epithelial stem/progenitor cell population of the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types.

An access system having a communication component that interfaces with a first device and a second device, where the first device is located inside or on an entity and coupled to a biological organism of the entity, and where the second device is located outside the entity and a controller component that controls a function of the first device, employing the communication component, to provide treatment to the biological organism of the entity coupled to the first device based on a request received from the second device.

The present invention relates to improvement of the yield of skin-derived pluripotent precursor cells in induction of differentiation of stem cells to skin-derived pluripotent precursor cells. The present invention provides a method for preparing skin-derived pluripotent precursor cell comprising culturing a neural crest stem cells in the presence of at least one selected from the group consisting of laminin and a fragment thereof to differentiate the cells to skin-derived pluripotent precursor cells, wherein the laminin is at least one selected from the group consisting of laminin 111, laminin 121, laminin 332, laminin 421, laminin 511, laminin 521, and a variant thereof.

An application of a transgenic stem cell-derived exosome in preparing a medicament or whitening cosmetic is provided. In the present disclosure, miR-27b-3p is transfected into an epidermal stem cell, and a transgenic stem cell-derived exosome is harvested. It is experimentally verified that the exosome can inhibit the expression of PIK3R3 protein in melanocytes and the proliferation and migration of melanocytes; and safety experiments further demonstrate the safety of the exosome. Therefore, corresponding medicaments or cosmetics prepared from the exosome have excellent medicinal and cosmetic application prospects.

The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.

The present invention relates to a method of cultivating stem/progenitor cells of the amniotic membrane of umbilical cord that comprises obtaining a tissue explant from the amniotic membrane of umbilical cord and cultivating the tissue explant in suitable cultivation media and cultivation conditions over a suitable period of time. The method may include isolating the stem/progenitor cells from the tissue cultures. The stem cells may be epithelial or mesenchymal stem/progenitor cells. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes.

An application of a transgenic stem cell-derived exosome in preparing a medicament or whitening cosmetic is provided. In the present disclosure, miR-27b-3p is transfected into an epidermal stem cell, and a transgenic stem cell-derived exosome is harvested. It is experimentally verified that the exosome can inhibit the expression of PIK3R3 protein in melanocytes and the proliferation and migration of melanocytes; and safety experiments further demonstrate the safety of the exosome. Therefore, corresponding medicaments or cosmetics prepared from the exosome have excellent medicinal and cosmetic application prospects.

The present disclosure concerns an in-vitro full skin model which comprises a dermal equivalent and epidermal equivalent as well as from about 1 to about 100 three-dimensional sweat gland equivalents with respectively from about 500 to about 500000 sweat gland cells as well as a diameter of respectively from about 100 to about 6000 μm on a supporting layer. Furthermore, the present disclosure concerns the production of the full skin model as well as the use of this model as an in-vitro model, in screening methods as well as for in-vitro evaluation of the influence of cosmetic substances on the inhibition of sweat secretion as well as body odor.

Sebaceous gland-like organoids comprising a Blimp1 positive cell are provided. Methods of producing the organoids and using the organoids to test a skin drug are also provided; as are methods of treating acne.